Swedish health-tech company Brighter AB (Nasdaq First North Growth Market:BRIG) said on Wednesday that it has signed an agreement with the Northern Care Alliance NHS Foundation Trust in the UK for a funded-research study with Actiste Diabetes Management as a Service (ADMS) in the city of Salford.
This study is a high-level clinical-research project that the company hopes will confirm scientifically relevant insights about the benefits that Actiste can provide for the management of both type 1 and type 2 insulin-treated diabetes.
The research data will be shared with the diabetes scientific community, front-line care providers, patients, health-insurance companies and partners.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA